An evaluation of self-efficacy of patients with chronic pain attending a community based exercise program.

Not Applicable

• Conditions: chronic pain; Musculoskeletal - Other muscular and skeletal disorders; Physical Medicine / Rehabilitation - Physiotherapy; Neurological - Neurodegenerative diseases

• Registration Number: ACTRN12618000043235
• Lead Sponsor: Macquarie University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-01-15
• Study Completion: 2018-12-11
• Last Update Posted: 3 February 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

1Chronic pain which may or may not be back pain (is pain lasting > 3 months duration)
2VAS greater than or equal to 2
3Be able to read and understand written and spoken English
4Have completed their Initial Assessments at Physiocise in the four weeks prior to the commencement of the exercise class.
5Be 18 years or older
6Have access to the internet for the 3 month email follow up
7 Be able to participate the full ten weeks of the Physiocise Foundations program

Exclusion Criteria

1Currently pregnant
2Low back pain that is attributable to a recognisable known specific pathology (eg infection, tumour, fracture, inflammatory disorder).

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
changes in self efficacy as measured by VAS confidence scores [Immediately post-program at Week 10 (primary endpoint) and at 3 month follow up];changes in pain self-efficacy as measured with PSEQ (Pain Self Efficacy Questionnaire) . PSEQ is a validated study developed by Michael Nicholas[Immediately post-program at Week 10 (primary endpoint) and at 3 month follow up];changes in goal attainment score as measured with GAS[Immediately post-program at Week 10 (primary endpoint) and at 3 month follow up]

Secondary Outcome Measures

Name	Time	Method
changes to pain bothersomeness as measured with the 'bothersome score' which is a scale that has been validated for use.[Immediately post-program at Week 10 and at 3 month follow up];changes to patient function as measured with the PSFS (patient specific functional score) which is validated scale.[Immediately post-program at Week 10 and at 3 month follow up];changes to fear avoidance behaviours as measured with tampa questionnaire[Immediately post-program at Week 10 and at 3 month follow up];changes to disability as measured with roland morris disability questionnaire[Immediately post-program at Week 10 and at 3 month follow up];changes to pain as measured with a pain visual analogue score[Immediately post-program at Week 10 and at 3 month follow up]